News Releases

CHICAGO --(BUSINESS WIRE)--Feb. 9, 2022-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R.

Recorlev ® (levoketoconazole) now exclusively available through PANTHERx Rare Specialty Pharmacy To increase patient access to Recorlev, the Company has established Xeris CareConnection™, a comprehensive support program, which includes $0 co-pay for commercially insured patients, one-on-one support

  Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million 20+ million Medicaid lives in IL, TN, PA, OH, and CA have

CHICAGO --(BUSINESS WIRE)--Jan. 6, 2022-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R.

CHICAGO --(BUSINESS WIRE)--Jan. 3, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January